Ligand-Payload Conjugate Linkers for Stable High-DAR Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ligand-payload conjugates face challenges in achieving optimal stability and therapeutic index, particularly for less hydrophobic payloads, necessitating the development of novel conjugates with enhanced linker-payload stability and increased efficacy.
Innovation Solution
The development of ligand-payload conjugates with specifically designed linkers that enhance stability and therapeutic index, including compounds represented by formulas (I), (I*), (II), (II*), (III), and (III*), which are synthesized through reacting linker-payload compounds with ligands, and administered to treat diseases or disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If higher DAR (drug-to-antibody ratio) is used for less hydrophobic payloads, then loading capacity increases, but linker-payload stability decreases
Solution Approach 1:
The patent changes the chemical parameters of the linker structure to achieve optimal stability at higher DAR values. Specifically, it employs linkers with controlled hydrophobicity, specific amino acid compositions (such as glutamine, leucine, isoleucine), and defined structural features (cyclic vs linear, charged vs neutral) that maintain stability even when 8 or more drug molecules are conjugated per antibody, thereby resolving the contradiction between loading capacity and stability.
2Reliability
If more drug molecules are conjugated per antibody, then therapeutic index increases, but ADC stability decreases
Solution Approach 1:
The patent optimizes linker parameters including hydrophobicity (logP values), amino acid composition ratios (e.g., Q:X ratios where Q is glutamine and X is other amino acids), and structural characteristics to achieve high therapeutic indices with stable ADC constructs containing 2-12 drug molecules per antibody, depending on payload hydrophobicity.
Solution Approach 2:
The patent creates composite linker structures combining multiple amino acid types (glutamine, leucine, isoleucine, and others) with specific structural features (cyclic moieties, charged groups) to achieve synergistic effects that simultaneously enhance ADC stability and therapeutic index at high drug loading ratios.
3Quantity of substance
If heavily loaded conjugates are used, then drug delivery capacity increases, but in vivo efficacy and tolerability worsen
Solution Approach 1:
The patent identifies and optimizes critical linker parameters including hydrophobicity (targeting specific logP ranges), amino acid composition (specific ratios of glutamine to other amino acids), and structural features (cyclic versus linear configurations) to achieve optimal in vivo performance. These parameter optimizations ensure that heavily loaded ADCs (with 8+ drugs per antibody for less hydrophobic payloads) maintain stability, efficacy, and tolerability by preventing premature drug release and reducing off-target effects.
Data Source
AI summary
The present disclosure relates to ligand-payload conjugates, and compositions and use thereof for treating diseases, disorders, or conditions, such as cancers, autoimmune diseases, or infectious diseases. The present disclosure also provides methods of synthesizing ligand-payload conjugates, and related intermediates.